E
Edmond Chouinard
Researcher at Memorial Hospital of South Bend
Publications - 6
Citations - 429
Edmond Chouinard is an academic researcher from Memorial Hospital of South Bend. The author has contributed to research in topics: Exemestane & Cancer. The author has an hindex of 4, co-authored 6 publications receiving 411 citations. Previous affiliations of Edmond Chouinard include University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Helping Patients Make Informed Choices: A Randomized Trial of a Decision Aid for Adjuvant Chemotherapy in Lymph Node-Negative Breast Cancer
Timothy J. Whelan,Carol Sawka,Mark Levine,Amiram Gafni,Leonard M. Reyno,Andrew R. Willan,Jim A. Julian,Susan Dent,H. Abu-Zahra,Edmond Chouinard,Richard Tozer,Kathleen I. Pritchard,Ilona Bodendorfer +12 more
TL;DR: When making decisions regarding adjuvant chemotherapy, patients with early breast cancer who had been exposed to the Decision Board had better knowledge of the disease and treatment options and greater satisfaction with their decision making than those who received the standard consultation.
Journal ArticleDOI
Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2
Hope S. Rugo,Kathleen I. Pritchard,Michael Gnant,Shinzaburo Noguchi,Martine Piccart,Gabriel N. Hortobagyi,José Baselga,Alejandra T. Perez,Matthias Geberth,Tibor Csoszi,Edmond Chouinard,Vichien Srimuninnimit,Puttisak Puttawibul,Janice F. Eakle,Wentao Feng,H. Bauly,Mona El-Hashimy,Tetiana Taran,Howard A. Burris +18 more
TL;DR: The BOLERO-2 trial demonstrated that adding everolimus to exemestane substantially improved clinical benefit with acceptable safety in postmenopausal women with HR+ breast cancer relapsing/progressing on a nonsteroidal aromatase inhibitor.
Journal ArticleDOI
Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial.
Howard A. Burris,Fabienne Lebrun,Hope S. Rugo,J. Thaddeus Beck,Martine Piccart,Patrick Neven,José Baselga,Katarína Petráková,Gabriel N. Hortobagyi,Anna Komorowski,Edmond Chouinard,Robyn R. Young,Michael Gnant,Kathleen I. Pritchard,Lee Bennett,Jean-Francois Ricci,H. Bauly,Tetiana Taran,Tarek Sahmoud,Shinzaburo Noguchi +19 more
TL;DR: This analysis investigated the treatment effects on health‐related quality of life (HRQOL) in patients with advanced breast cancer who developed disease progression after treatment with nonsteroidal aromatase inhibitors.
Journal ArticleDOI
BOLERO-2: Health-related quality-of-life (HRQoL) in metastatic breast cancer patients treated with everolimus and exemestane versus exemestane.
Hope S. Rugo,J. Thaddeus Beck,José Baselga,Shinzaburo Noguchi,M. Gnant,Fabienne Lebrun,Patrick Neven,Martina Nunzi,Anna Komorowski,Edmond Chouinard,Robyn R. Young,Ian Churchill Anderson,Lee Bennett,Jean-Francois Ricci,Gabriel N. Hortobagyi,Tarek Sahmoud,Howard A. Burris +16 more
TL;DR: It was demonstrated that EVE + EXE significantly improved progression-free survival (PFS) vs EXE + placebo, but EVE + exemestane resulted in a higher rate of grade 3-4 toxicity.
Journal ArticleDOI
Patient-reported physical, emotional, and social functioning in advanced breast cancer: Insights from BOLERO-2.
Denise A. Yardley,Gabriel N. Hortobagyi,Fabienne Lebrun,J. Thaddeus Beck,Patrick Neven,José Baselga,Katarína Petráková,Shaker R. Dakhil,Silvia Sabatini,Anna Komorowski,Edmond Chouinard,Robyn R. Young,M. Gnant,Kathleen I. Pritchard,Jie Zhang,Ryan Ziemiecki,Ashok Panneerselvam,Tanya Taran,Tarek Sahmoud,Shinzaburo Noguchi +19 more
TL;DR: A higher rate of grade 3/4 adverse events was noted with EVE + EXE but was not associated with deterioration in quality of life (QOL) based on the EORTC QLQ-C30 Global Health Status scale.